Spruce Biosciences, Inc. Share Price
NASDAQ: SPRB | Micro CapSpruce Biosciences, Inc. Stock Performance
Open $46.60 | Prev. Close $46.66 | Circuit Range N/A |
Day Range $46.60 - $46.60 | Year Range $8.55 - $234.75 | Volume 1,290 |
Average Traded $46.60 |
Spruce Biosciences, Inc. Share Price Today
As of 9 August 2026, Spruce Biosciences, Inc.'s share price is $46.54. The stock opened at $46.60, compared to its previous close of $46.66. During today's trading session, Spruce Biosciences, Inc.'s share price traded between $46.60 and $46.60, with an average price of $46.60. Over the past 52 weeks, the stock has recorded a high of $234.75 and a low of $8.55. In terms of performance, Spruce Biosciences, Inc.'s share price has declined by 21.48% over the last six months and is up 59566.67% on a year-on-year basis.
Spruce Biosciences, Inc. Share Price Chart
Spruce Biosciences, Inc. Stock Fundamentals & Key Indicators
Market Cap $35.68M | PE Ratio (TTM) -0.92 | Dividend Yield N/A |
EPS (TTM) $-50.83 | Revenue (TTM) N/A | Return On Equity (TTM) -91.65% |
Profit Margin N/A | Debt to Equity 0.24 | Quarterly Earnings Growth YoY 5.29% |
Spruce Biosciences, Inc. Quarterly Profit & Loss
All figures in USD
Spruce Biosciences, Inc. Annual Profit & Loss
All figures in USD
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Spruce Biosciences, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $41.98 | $46.66 | +8.97% |
Jul 2026 | $51.69 | $42.83 | -21.90% |
Jun 2026 | $52.51 | $54.84 | +10.95% |
May 2026 | $58.25 | $49.42 | -13.23% |
Apr 2026 | $68.02 | $56.96 | -11.03% |
Mar 2026 | $53.36 | $64.02 | +8.01% |
Feb 2026 | $80.95 | $59.27 | -28.25% |
Jan 2026 | $83.02 | $82.61 | -2.17% |
Dec 2025 | $96.59 | $84.44 | -14.54% |
Nov 2025 | $107.00 | $98.81 | -8.08% |
Oct 2025 | $35.13 | $107.50 | +1,064.68% |
Sep 2025 | $8.60 | $9.23 | +11,733.33% |
SPRB Share Price FAQs
What is Spruce Biosciences, Inc. share price today?
What is the 52 week high and 52 week low of Spruce Biosciences, Inc. stock?
What is SPRB's market capitalisation today?
What is SPRB's net income for the last quarter?
What is the 5 year returns of SPRB?
What is the high & low stock price of SPRB today?
Can I buy SPRB shares in India?